2024
The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment
Schoretsanitis G, Correll C, Agorastos A, Sanchez A, Erzin G, Grigoras R, Benussi M, Gondek T, Guloksuz S, Højlund M, Jerotic S, Kilic O, Metaj E, Sidhu D, Skandali N, Skuhareuski A, Tveito M, Wolthusen R, Communication and Publications E, Chumakov E, de Filippis R. The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment. The World Journal Of Biological Psychiatry 2024, 25: 342-351. PMID: 38905131, DOI: 10.1080/15622975.2024.2367138.Peer-Reviewed Original ResearchConceptsEuropean Psychiatric AssociationAntipsychotic treatmentPsychiatrists' attitudesTherapeutic drug monitoringEarly-career psychiatristsExploratory factor analysisBenefit of therapeutic drug monitoringPsychiatric AssociationAntipsychoticsNegative expectationsAssociated with frequencyTDM useDrug monitoringTherapeutic drug monitoring useFactor analysisBeliefs of patientsHigh-income countriesLow-/middle-income countriesResponse varianceClinical benefitClozapineOutpatient settingLinear regression analysisClinical settingPsychiatrists
2019
Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study
van Os J, Pries L, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine 2019, 50: 1884-1897. PMID: 31414981, DOI: 10.1017/s003329171900196x.Peer-Reviewed Original ResearchConceptsPsychotic disordersPolygenic riskSchizophrenia polygenic riskGene-environment interactionsGenetic riskRelatives of patientsFirst-degree relativesPsychosis phenotypeAverage genetic riskIntermediate phenotypesHealthy siblingsCognitive intermediate phenotypesControl groupAnalysis of associationAverage riskPatientsPhenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)
Pandit R, Cianci D, Hark S, Rossum I, Ebdrup B, Broberg B, Garcia‐Portilla M, Bobes J, Vinkers C, Kahn R, Guloksuz S, Huitema A, Luykx J. Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatrica Scandinavica 2019, 140: 283-290. PMID: 31323113, PMCID: PMC6771865, DOI: 10.1111/acps.13074.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis patientsPsychosis patientsWeight gainSchizophreniform disorderAntipsychotic-induced weight gainFirst-episode patientsManagement of schizophreniaLower baseline weightMultivariable regression modelsWeight-reducing strategiesOptimization of treatmentRegression modelsMajor depression disorderPhenotypic factorsAmisulpride treatmentBaseline weightEurope (Syst-Eur) trialMost antipsychoticsDepression disorderYoung subjectsBody weightPatientsBetter efficacyYounger ageAIWG
2015
Pharmaceutical industry interactions of psychiatric trainees from 20 European countries
Riese F, Guloksuz S, Roventa C, Fair J, Haravuori H, Rolko T, Flynn D, Giacco D, Banjac V, Jovanovic N, Bayat N, Palumbo C, Rusaka M, Kilic O, Augėnaitė J, Nawka A, Zenger M, Kekin I, Wuyts P, Barrett E, Bausch-Becker N, Mikaliūnas J, del Valle E, Feffer K, Lomax G, Marques J, Jauhar S. Pharmaceutical industry interactions of psychiatric trainees from 20 European countries. European Psychiatry 2015, 30: 284-290. PMID: 25456156, DOI: 10.1016/j.eurpsy.2014.09.417.Peer-Reviewed Original Research
2012
Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
Jauhar S, Guloksuz S, Andlauer O, Lydall G, Marques J, Mendonca L, Dumitrescu I, Roventa C, De Vriendt N, Van Zanten J, Riese F, Nwachukwu I, Nawka A, Psaras R, Masson N, Krishnadas R, Volpe U, European Federation of Psychiatric Trainees' Research Group. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? BMC Psychiatry 2012, 12: 27. PMID: 22463055, PMCID: PMC3337226, DOI: 10.1186/1471-244x-12-27.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsCognitive behavioral therapyUse of SGAsSecond-generation antipsychotic medicationsKnowledge of trialQuestionnaire-based studyAntipsychotic medicationAntipsychotic treatmentTreatment choicePatientsBehavioral therapyForms of psychotherapyOwn treatmentAntipsychoticsTreatmentPsychosisTrialsPsychiatry traineesEfficacyTrainees